|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM327983507 |
| 003 |
DE-627 |
| 005 |
20250302040640.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108795
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1093.xml
|
| 035 |
|
|
|a (DE-627)NLM327983507
|
| 035 |
|
|
|a (NLM)34252574
|
| 035 |
|
|
|a (PII)S1521-6616(21)00132-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Jamaly, Simin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.08.2021
|
| 500 |
|
|
|a Date Revised 19.08.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a CommentIn: Nat Rev Nephrol. 2021 Sep;17(9):572. doi: 10.1038/s41581-021-00469-5. - PMID 34312512
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Acute and chronic kidney failure is common in hospitalized patients with COVID-19, yet the mechanism of injury and predisposing factors remain poorly understood. We investigated the role of complement activation by determining the levels of deposited complement components (C1q, C3, FH, C5b-9) and immunoglobulin along with the expression levels of the injury-associated molecules spleen tyrosine kinase (Syk), mucin-1 (MUC1) and calcium/calmodulin-dependent protein kinase IV (CaMK4) in the kidney tissues of people who succumbed to COVID-19. We report increased deposition of C1q, C3, C5b-9, total immunoglobulin, and high expression levels of Syk, MUC1 and CaMK4 in the kidneys of COVID-19 patients. Our study provides strong rationale for the expansion of trials involving the use of inhibitors of these molecules, in particular C1q, C3, Syk, MUC1 and CaMK4 to treat patients with COVID-19
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a CaMK4
|
| 650 |
|
4 |
|a Complement activation
|
| 650 |
|
4 |
|a Immune complexes
|
| 650 |
|
4 |
|a Kidney injury
|
| 650 |
|
4 |
|a MUC1
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
4 |
|a Syk
|
| 650 |
|
7 |
|a Mucin-1
|2 NLM
|
| 650 |
|
7 |
|a Complement System Proteins
|2 NLM
|
| 650 |
|
7 |
|a 9007-36-7
|2 NLM
|
| 650 |
|
7 |
|a SYK protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 650 |
|
7 |
|a Syk Kinase
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 650 |
|
7 |
|a CAMK4 protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.17
|2 NLM
|
| 650 |
|
7 |
|a Calcium-Calmodulin-Dependent Protein Kinase Type 4
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.17
|2 NLM
|
| 700 |
1 |
|
|a Tsokos, Maria G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bhargava, Rhea
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brook, Olga R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hecht, Jonathan L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Abdi, Reza
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Moulton, Vaishali R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Satyam, Abhigyan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tsokos, George C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 229(2021) vom: 15. Aug., Seite 108795
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:229
|g year:2021
|g day:15
|g month:08
|g pages:108795
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108795
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 229
|j 2021
|b 15
|c 08
|h 108795
|